Skip to content
Disclosery

M28 Capital Management LP

Follow

13F filer, CIK 1807489, STAMFORD, CT

M28 Capital Management LP reported $53,799,035 across 9 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000902664-26-002442

Period
2026-03-31
Reported value
$53.8M
Holdings
9
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
WVEreduced-1,076,264-$7.8M
TGTXreduced-73,246-$2.43M
ARWRreduced-30,549-$1.92M
PRQRreduced-419,705-$680K
RCKTreduced-174,809-$626K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0000902664-26-002442, largest first. % of portfolio is the value over $53,799,035, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
WVEWAVE LIFE SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 6,164,548 shares; 2024Q4: 5,664,548 shares; 2025Q1: 5,664,548 shares; 2025Q2: 5,664,548 shares; 2025Q3: 5,664,548 shares; 2025Q4: 5,664,548 shares; 2026Q1: 4,588,284 shares 4,588,284$33.3M61.83%-1,076,264Timeline
IVVDINVIVYD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 9,248,250 shares; 2024Q4: 9,248,250 shares; 2025Q1: 9,248,250 shares; 2025Q2: 9,248,250 shares; 2025Q3: 9,248,250 shares; 2025Q4: 9,248,250 shares; 2026Q1: 9,248,250 shares 9,248,250$12M22.35%0Timeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 161,600 shares; 2024Q4: 161,600 shares; 2025Q1: 161,600 shares; 2025Q2: 161,600 shares; 2025Q3: 161,600 shares; 2025Q4: 161,600 shares; 2026Q1: 88,354 shares 88,354$2.94M5.46%-73,246Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 67,400 shares; 2024Q4: 67,400 shares; 2025Q1: 67,400 shares; 2025Q2: 67,400 shares; 2025Q3: 67,400 shares; 2025Q4: 67,400 shares; 2026Q1: 36,851 shares 36,851$2.31M4.29%-30,549Timeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,019,498 shares; 2024Q4: 1,019,498 shares; 2025Q1: 1,019,498 shares; 2025Q2: 1,019,498 shares; 2025Q3: 1,019,498 shares; 2025Q4: 1,019,498 shares; 2026Q1: 599,793 shares 599,793$972K1.81%-419,705Timeline
GUTSFRACTYL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,856,117 shares; 2024Q4: 1,856,117 shares; 2025Q1: 1,856,117 shares; 2025Q2: 1,856,117 shares; 2025Q3: 1,856,117 shares; 2025Q4: 1,856,117 shares; 2026Q1: 1,856,117 shares 1,856,117$850K1.58%0Timeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 385,680 shares; 2024Q4: 385,680 shares; 2025Q1: 385,680 shares; 2025Q2: 385,680 shares; 2025Q3: 385,680 shares; 2025Q4: 385,680 shares; 2026Q1: 210,871 shares 210,871$755K1.4%-174,809Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 185,100 shares; 2024Q4: 185,100 shares; 2025Q1: 185,100 shares; 2025Q2: 185,100 shares; 2025Q3: 185,100 shares; 2025Q4: 185,100 shares; 2026Q1: 101,203 shares 101,203$533K0.99%-83,897Timeline
CRISCURIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 421,951 shares; 2024Q4: 521,059 shares; 2025Q1: 521,059 shares; 2025Q2: 521,059 shares; 2025Q3: 521,059 shares; 2025Q4: 521,059 shares; 2026Q1: 284,889 shares 284,889$156K0.29%-236,170Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000902664-26-002442 base2026-05-14acceptance time not in the bulk data set